Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Phathom Pharmaceuticals' Accounts Payables fell 8492.92% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 8492.92%. This contributed to the annual value of $10.5 million for FY2024, which is 1661.77% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Accounts Payables of $1.1 million as of Q3 2025, which was down 8492.92% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Accounts Payables ranged from a high of $12.6 million in Q4 2023 and a low of $1.1 million during Q3 2025
  • For the 4-year period, Phathom Pharmaceuticals' Accounts Payables averaged around $6.9 million, with its median value being $7.1 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 8342.12% in 2024, then crashed by 8492.92% in 2025.
  • Phathom Pharmaceuticals' Accounts Payables (Quarter) stood at $10.0 million in 2022, then grew by 26.05% to $12.6 million in 2023, then decreased by 16.62% to $10.5 million in 2024, then crashed by 89.77% to $1.1 million in 2025.
  • Its Accounts Payables was $1.1 million in Q3 2025, compared to $4.0 million in Q2 2025 and $11.6 million in Q1 2025.